Changsha Huamei Medical Technology Co., Ltd.

1) To evaluate the safety, tolerability and pharmacokinetic characteristics of single and multiple administrations of D(-) sulbenicillin sodium for injection in healthy subjects, to provide a safe dosage range for the dosing regimen of Phase II clinical trials, and to provide a basis for the formulation of a reasonable clinical regimen. 2) To compare the pharmacokinetic characteristics and urinary drug excretion of single administration of D(-) sulbenicillin sodium for injection and sulbenicillin sodium for injection containing the same dose of D(-) sulbenicillin sodium in healthy subjects.

The purpose of this study was to study the pharmacokinetic characteristics of the test preparations (levonidazole dispersible tablets and levonidazole capsules) developed and produced by Hunan Warner Pharmaceutical Co., Ltd. after single oral administration on an empty stomach or after meals, and to use the levonidazole tablets produced by Hunan Warner Pharmaceutical Co., Ltd. as the reference preparation to compare the pharmacokinetic parameters of the three preparations and evaluate the relative bioavailability and human bioequivalence of the two test preparations relative to the reference preparation.

The purpose of this study was to study the pharmacokinetic characteristics of the test preparations (levonidazole dispersible tablets and levonidazole capsules) developed and produced by Hunan Warner Pharmaceutical Co., Ltd. after single oral administration on an empty stomach or after meals, and to use the levonidazole tablets produced by Hunan Warner Pharmaceutical Co., Ltd. as the reference preparation to compare the pharmacokinetic parameters of the three preparations and evaluate the relative bioavailability and human bioequivalence of the two test preparations relative to the reference preparation.